FGFR2 and intrahepatic cholangiocarcinoma: In intrahepatic cholangiocarcinoma, FGFR2 fusions are identified in approximately 10–16% of cases, representing the most frequent and therapeutically relevant FGFR aberration in GI cancers [176].